Related Experiment Videos
[Systemic lupus erythematosus and antiphospholipid syndrome]
1Medizinisches Zentrum für Pathologie, Philipps-Universität, Marburg.
Der Pathologe
|November 1, 1996
Summary
Systemic lupus erythematosus (SLE) involves autoantibodies targeting nucleosomes. Diagnosis and prognosis of SLE and antiphospholipid syndrome (APS) benefit from morphologic analysis of biopsies, aiding therapeutic decisions.
Area of Science:
- Immunology
- Pathology
- Genetics
Context:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease driven by antinuclear antibodies.
- Nucleosomes are key antigens, triggering complement-activating complexes in SLE.
- Drug-induced SLE reveals mechanisms like DNA hypomethylation and altered cell interactions.
Purpose:
- To elucidate the pathogenesis of SLE and antiphospholipid syndrome (APS).
- To highlight the diagnostic and prognostic value of morphologic analysis in SLE.
- To explain the role of apoptosis disturbances and autoantibodies in SLE and APS.
Summary:
- SLE pathogenesis involves nucleosome autoantigens, DNA hypomethylation, altered immune cell interactions, and apoptosis defects.
- Morphologic examination of skin and renal biopsies, including activity and chronicity scores, aids SLE diagnosis, prognosis, and treatment.
- Antiphospholipid syndrome (APS), often secondary to SLE, involves antibodies against phospholipids and proteins like beta 2-glycoprotein 1, leading to thrombosis via mechanisms such as protein C pathway inhibition.
Impact:
- Morphologic assessment enhances SLE diagnosis, prognosis, and therapeutic strategies.
- Understanding SLE and APS mechanisms can lead to targeted therapies.
- This research provides insights into autoimmune disease pathogenesis and clinical management.